Exp Mol Med.
2006 Jun;38(3):320-324.
Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer
- Affiliations
-
- 1Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi-do 410-769, Korea.
- 2Department of Obstetrics and Gynecology, Ewha Womans University, Seoul 158-710, Korea.
- 3Department of Obstetrics and Gynecology, Seoul National University, Seoul 151-742, Korea. kjwksh@snu.ac.kr
- 4Cancer Research Institute, Seoul National University, Seoul 151-742, Korea.
- 5Human Genome Research Institute, Seoul National University, Seoul 151-742, Korea.
- 6Clinical Research Center for Solid Tumors, Goyang, Gyeonggi-do 410-769, Korea.
Abstract
- ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C->T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively. Using the SNapShot assay, we assessed this polymorphism in ERCC1 in 60 ovarian cancer patients. Platinum-resistance was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. Although not significant, platinum-resistance was less frequently observed in patients with the C/T+T/T genotype (P=0.064). Multivariate analysis showed that the C/T+T/T genotypes constituted an independent predictive factor of reduced risk of platinum-resistance in ovarian cancer (odds ratio 0.17, 95% confidence interval 0.04-0.74, P=0.018, Fisher's exact test). No significant correlation was observed between overall survival and the ERCC1 polymorphism. Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients. However, these findings require prospective confirmation.
Keyword
MeSH Terms
-
Survival Analysis
Polymorphism, Single Nucleotide/*genetics
Ovarian Neoplasms/drug therapy/*genetics/pathology
Multivariate Analysis
Middle Aged
Linkage Disequilibrium
Humans
Genotype
Gene Frequency
Female
Epithelial Cells/pathology
Endonucleases/*genetics
Drug Resistance, Neoplasm/genetics
Disease Progression
DNA-Binding Proteins/*genetics
DNA Repair
Codon/genetics
Cisplatin/*therapeutic use
Antineoplastic Agents/therapeutic use
Aged
Adult
Adolescent
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The role of topotecan as second-line chemotherapy in patients with recurrent epithelial ovarian cancer
- Secondary acute myeloid leukemia after platinum based chemotherapy for ovarian cancer
- ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC
- A Pilot Study of Platinum-based Three Cycle-Consolidation Chemotherapy in Epithelial Ovarian Cancer
- Efficacy and impact of PARPi monotherapy to subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
